|
1
|
Sehgal K, Dhodapkar KM and Dhodapkar MV:
Targeting human dendritic cells in situ to improve vaccines.
Immunol Lett. 162:59–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steinman RM: Some interfaces of dendritic
cell biology. APMIS. 111:675–697. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andrews DM, Scalzo AA, Yokoyama WM, Smyth
MJ and Degli-Esposti MA: Functional interactions between dendritic
cells and NK cells during viral infection. Nat Immunol. 4:175–181.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schirrmacher V, Ahlert T, Pröbstle T and
Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E and Steiner HH:
Immunization with virus-modified tumor cells. Semin Oncol.
25:677–696. 1998.PubMed/NCBI
|
|
5
|
Thara E, Dorff TB, Pinski JK and Quinn DI:
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Maturitas. 69:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohn L and Delamarre L: Dendritic
cell-targeted vaccines. Front Immunol. 5:2552014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guillerme JB, Boisgerault N, Roulois D,
Ménager J, Combredet C, Tangy F, Fonteneau JF and Gregoire M:
Measles virus vaccine-infected tumor cells induce tumor antigen
cross-presentation by human plasmacytoid dendritic cells. Clin
Cancer Res. 19:1147–1158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maamary J, Array F, Gao Q, García-Sastre
A, Steinman RM, Palese P and Nchinda G: Newcastle disease virus
expressing a dendritic cell-targeted HIV gag protein induces a
potent gag-specific immune response in mice. J Virol. 85:2235–2246.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fournier P and Schirrmacher V: Oncolytic
Newcastle Disease Virus as cutting edge between tumor and host.
Biology (Basel). 2:936–975. 2013.PubMed/NCBI
|
|
10
|
Melchjorsen J, Jensen SB, Malmgaard L,
Rasmussen SB, Weber F, Bowie AG, Matikainen S and Paludan SR:
Activation of innate defense against a paramyxovirus is mediated by
RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol.
79:12944–12951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato H, Sato S, Yoneyama M, Yamamoto M,
Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O
and Akira S: Cell type-specific involvement of RIG-I in antiviral
response. Immunity. 23:19–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fournier P, Arnold A and Schirrmacher V:
Polarization of human monocyte-derived dendritic cells to DC1 by in
vitro stimulation with Newcastle Disease Virus. J BUON. 14(Suppl
1): S111–S122. 2009.PubMed/NCBI
|
|
13
|
Austin FC and Boone CW: Virus augmentation
of the antigenicity of tumor cell extracts. Adv Cancer Res.
30:301–345. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sinkovics JG and Horvath JC: Virus therapy
of human cancers. Melanoma Res. 13:431–432. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brown JA, Dorfman DM, Ma FR, Sullivan EL,
Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of
programmed death-1 ligands on dendritic cells enhances T cell
activation and cytokine production. J Immunol. 170:1257–1266. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nguyen LT and Ohashi PS: Clinical blockade
of PD1 and LAG3 - potential mechanisms of action. Nat Rev Immunol.
15:45–56. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams EH, Williams CA and McLeod JD:
Identification of PDL-1 as a novel biomarker of sensitizer exposure
in dendritic-like cells. Toxicol In Vitro. 24:1727–1735. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalinski P, Edington H, Zeh HJ, Okada H,
Butterfield LH, Kirkwood JM and Bartlett DL: Dendritic cells in
cancer immunotherapy: Vaccines or autologous transplants? Immunol
Res. 50:235–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao F, Liu C, Guo J, Sun W, Xian L, Bai D,
Liu H, Cheng Y, Li B, Cui J, et al: Radiation-driven lipid
accumulation and dendritic cell dysfunction in cancer. Sci Rep.
5:96132015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reichardt P, Dornbach B and Gunzer M: APC,
T cells, and the immune synapse. Curr Top Microbiol Immunol.
340:229–249. 2010.PubMed/NCBI
|
|
23
|
Linette GP and Carreno BM: Dendritic
cell-based vaccines: Shining the spotlight on signal 3.
Oncoimmunology. 2:e265122013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Talay O, Shen CH, Chen L and Chen J: B7-H1
(PD-L1) on T cells is required for T-cell-mediated conditioning of
dendritic cell maturation. Proc Natl Acad Sci USA. 106:2741–2746.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang SC, Latchman YE, Buhlmann JE,
Tomczak MF, Horwitz BH, Freeman GJ and Sharpe AH: Regulation of
PD-1, PD-L1, and PD-L2 expression during normal and autoimmune
responses. Eur J Immunol. 33:2706–2716. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rodig N, Ryan T, Allen JA, Pang H, Grabie
N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH and
Freeman GJ: Endothelial expression of PD-L1 and PD-L2
down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol.
33:3117–3126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goto T, Nishida T, Takagi E, Miyao K,
Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura
S, et al: Programmed death-ligand 1 on antigen-presenting cells
facilitates the induction of antigen-specific cytotoxic T
lymphocytes: Application to adoptive T-cell immunotherapy. J
Immunother. 39:306–315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martin-Orozco N, Wang YH, Yagita H and
Dong C: Cutting Edge: Programmed death (PD) ligand-1/PD-1
interaction is required for CD8+ T cell tolerance to tissue
antigens. J Immunol. 177:8291–8295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okazaki T and Honjo T: The PD-1-PD-L
pathway in immunological tolerance. Trends Immunol. 27:195–201.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Millán O, Rafael-Valdivia L, Torrademé E,
López A, Fortuna V, Sánchez-Cabus S, López-Púa Y, Rimola A and
Brunet M: Intracellular IFN-gamma and IL-2 expression monitoring as
surrogate markers of the risk of acute rejection and personal drug
response in de novo liver transplant recipients. Cytokine.
61:556–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shimoda M, Tomimaru Y, Charpentier KP,
Safran H, Carlson RI and Wands J: Tumor progression-related
transmembrane protein aspartate-β-hydroxylase is a target for
immunotherapy of hepatocellular carcinoma. J Hepatol. 56:1129–1135.
2012. View Article : Google Scholar : PubMed/NCBI
|
